EMA streamlines procedures amid "challenging" economic climate
This article was originally published in Scrip
Executive Summary
Faced with budget constraints and an ever-growing workload, the European Medicines Agency is reorganizing its internal processes in a bid to make them more efficient while increasing the overall quality of its work. The move includes the creation of two new senior positions to allow individual products to be more closely shepherded through the EMA drug evaluation process.